A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
Daniel H. Ahn, Pedro Luiz Serrano Usón, Peter Masci, Heidi Kosiorek, Þorvarður R. Hálfdánarson, Kabir Mody, Hani M. Babiker, Thomas DeLeon, Mohamad Bassam Sonbol, Gregory Gores, Rory L. Smoot, Tanios Bekaii‐Saab, Amit Mahipal, Aaron S. Mansfield, Nguyen H. Tran, Joleen M. Hubbard, Mitesh J. Borad
Topics & Concepts
PonatinibMedicineInternal medicineFibroblast growth factor receptorOncologyRefractory (planetary science)Tyrosine-kinase inhibitorCancerTyrosine kinaseFibroblast growth factorBiologyNilotinibReceptorAstrobiologyCholangiocarcinoma and Gallbladder Cancer StudiesFibroblast Growth Factor ResearchPancreatic and Hepatic Oncology Research